Items where Division is "03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Cancer Immunology and Biology (Zippelius/Rochlitz)"
Number of items at this level: 18.
Martin, Kea Simone. Microtubule-depolymerizing agents potentiate anti-tumor immunity by stimulation of dendritic cells. 2015, PhD Thesis, University of Basel, Faculty of Science.
Romer, A. and Seiler, D. and Marincek, N. and Brunner, P. and Koller, M. T. and Ng, Q. K. T. and Maecke, H. R. and Müller-Brand, J. and Rochlitz, C. and Briel, M. and Schindler, C. and Walter, M. A.. (2014) Somatostatin-based radiopeptide therapy with [(177)Lu-DOTA]-TOC versus [ (90)Y-DOTA]-TOC in neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, Vol. 41, H. 2. S. 214-222.
Tse, B. W. and Collins, A. and Oehler, M. K. and Zippelius, A. and Heinzelmann-Schwarz, V. A.. (2014) Antibody-based immunotherapy for ovarian cancer: where are we at? Annals of oncology, Vol. 25, H. 2. S. 322-331.
Bontognali, S. and Pless, M. and Brutsche, M. H. and Fischer, C. and Rochlitz, C. and Buess, M.. (2013) Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib. Onkologie, Vol. 36, H. 4. S. 161-166.
Marincek, N. and Jorg, A. C. and Brunner, P. and Schindler, C. and Koller, M. T. and Rochlitz, C. and Muller-Brand, J. and Maecke, H. R. and Briel, M. and Walter, M. A.. (2013) Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors : long-term outcome of a phase I dose escalation study. Journal of translational medicine, Vol. 11 , 17. S. 17.
Mamot, C. and Ritschard, R. and Wicki, A. and Kung, W. and Schuller, J. and Herrmann, R. and Rochlitz, C.. (2012) Immunoliposomal delivery of doxorubicin can overcome multidrug resistance mechanisms in EGFR-overexpressing tumor cells. Journal of drug targeting, Vol. 20, H. 5. S. 422-432.
Mamot, C. and Ritschard, R. and Wicki, A. and Stehle, G. and Dieterle, T. and Bubendorf, L. and Hilker, C. and Deuster, S. and Herrmann, R. and Rochlitz, C.. (2012) Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. The Lancet oncology, Vol. 13, H. 12. S. 1234-1241.
Rajski, M. and Vogel, B. and Baty, F. and Rochlitz, C. and Buess, M.. (2012) Global gene expression analysis of the interaction between cancer cells and osteoblasts to predict bone metastasis in breast cancer. PLoS one, Vol. 7, H. 1 , e29743.
Wicki, A. and Rochlitz, C.. (2012) Targeted therapies in breast cancer. Swiss medical weekly, Vol. 142 , w13550.
Wicki, Andreas and Rochlitz, Christoph and Orleth, Annette and Ritschard, Reto and Albrecht, Imke and Herrmann, Richard and Christofori, Gerhard and Mamot, Christoph. (2012) Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clinical cancer research, Vol. 18, no. 18. S. 454-464.
Rochlitz, C. and Ruhstaller, T. and Lerch, S. and Spirig, C. and Huober, J. and Suter, T. and Buhlmann, M. and Fehr, M. and Schonenberger, A. and von Moos, R. and Winterhalder, R. and Rauch, D. and Muller, A. and Mannhart-Harms, M. and Herrmann, R. and Cliffe, B. and Mayer, M. and Zaman, K.. (2011) Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer : a multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, Vol. 22, H. 1. S. 80-85.
Burckhart, Tanja and Thiel, Markus and Nishikawa, Hiroyoshi and Wüest, Thomas and Müller, Dafne and Zippelius, Alfred and Ritter, Gerd and Old, Lloyd and Shiku, Hiroshi and Renner, Christoph. (2010) Tumor-specific crosslinking of GITR as costimulation for immunotherapy. Journal of immunotherapy, Vol. 33, H. 9. S. 925-934.
Rajski, M. and Zanetti-Dallenbach, R. and Vogel, B. and Herrmann, R. and Rochlitz, C. and Buess, M.. (2010) IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC medicine, Vol. 8. S. 1.
Speiser, Daniel E. and Schwarz, Katrin and Baumgaertner, Petra and Manolova, Vania and Devevre, Estelle and Sterry, Wolfram and Walden, Peter and Zippelius, Alfred and Conzett, Katrin Baumann and Senti, Gabriela and Voelter, Verena and Cerottini, Jean-Philippe and Guggisberg, David and Willers, Jörg and Geldhof, Christine and Romero, Pedro and Kündig, Thomas and Knuth, Alexander and Dummer, Reinhard and Trefzer, Uwe and Bachmann, Martin F.. (2010) Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. Journal of immunotherapy, Vol. 33, H. 8. S. 848-858.
Knights, Ashley J. and Nuber, Natko and Thomson, Christopher W. and de la Rosa, Olga and Jäger, Elke and Tiercy, Jean-Marie and van den Broek, Maries and Pascolo, Steve and Knuth, Alexander and Zippelius, Alfred. (2009) Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer immunology, immunotherapy, Vol. 58. S. 325-338.
Curioni-Fontecedro, A. and Knights, A. J. and Tinguely, M. and Nuber, N. and Schneider, C. and Thomson, C. W. and von Boehmer, L. and Bossart, W. and Pahlich, S. and Gehring, H. and Moch, H. and Renner, C. and Knuth, A. and Zippelius, A.. (2008) MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia, Vol. 22, no. 8. S. 1646-1648.
Dummer, R. and Rochlitz, C. and Velu, T. and Acres, B. and Limacher, J. M. and Bleuzen, P. and Lacoste, G. and Slos, P. and Romero, P. and Urosevic, M.. (2008) Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Molecular therapy, Vol. 16, H. 5. S. 985-994.
Tinguely, M. and Jenni, B. and Knights, A. and Lopes, B. and Korol, D. and Rousson, V. and Curioni Fontecedro, A. and Cogliatti, S. B. and Bittermann, A. G. and Schmid, U. and Dommann-Scherrer, C. and Maurer, R. and Renner, C. and Probst-Hensch, N. M. and Moch, H. and Knuth, A. and Zippelius, A.. (2008) MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer science, Vol. 99, H. 4. S. 720-725.